Serum levels of insulin-like growth factor-1 and insulin-like growth factor binding protein-3 in relapsing and primary progressive multiple sclerosis

Abstract

Using radioimmunoassay we measured serum levels of insulin-like growth factor (IGF)-1 and IGF binding protein (IGFBP)-3 in patients with relapsing multiple sclerosis (MS) and a benign course (Expanded Disability Status Scale (EDSS)≤ 3 despite > 10 years disease duration), relapsing MS with cumulative disability leading to an EDSS score > 4 within 10 years of disease duration, primary progressive MS and healthy controls. We found no differences in IGF-1 and IGFBP-3 serum levels, and the IGF-1/IGFBP-3 ratio between the four groups. However, there was a significant correlation (P=0.005) between IGFBP-3 serum levels and both the progression index of disability and the Multiple Sclerosis Severity Score in patients with primary progressive MS.

Keywords

disease progression insulin-like growth factor insulin-like growth factor binding protein-3 multiple sclerosis primary progressive MS

Get full access to this article

View all access options for this article.

References

Roth GA , Spada V , Hamill K , Bornstein MB. Insulin-like growth factor I increases myelination and inhibits demyelination in cultured organotypic nerve tissue . Brain Res Dev Brain Res 1995; 88: 102-108 .

McMorris FA , Smith TM , DeSalvo S , Furlanetto RW. Insulin-like growth factor I/somatomedin C: a potent inducer of oligodendrocyte development . Proc Natl Acad Sci USA 1986; 83: 822-826 .

Mason JL , Ye P , Suzuki K , D’Ercole AJ , Matsushima GK. Insulin-like growth factor-1 inhibits mature oligodendrocyte apoptosis during primary demyelination . J Neurosci 2000; 20: 5703-5708 .

Barres BA , Hart IK , Coles HS , Burne JF , Voyvodic JT , Richardson WD et al. Cell death and control of cell survival in the oligodendrocyte lineage . Cell 1992; 70: 31-46 .

Wilczak N , Schaaf M , Bredewold R , Streefland C , Teelken A , De Keyser J. Insulin-like growth factor system in serum and cerebrospinal fluid in patients with multiple sclerosis . Neurosci Lett 1998; 257: 168-170 .

Torres-Aleman I , Barrios V , Berciano J. The peripheral insulin-like growth factor system in amyotrophic lateral sclerosis and in multiple sclerosis . Neurology 1998; 50: 772-776 .

Poser CM , Paty DW , Scheinberg L , McDonald WI , Davis FA , Ebers GC et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols . Ann Neurol 1983; 13: 227-231 .

Thompson AJ , Montalban X , Barkhof F , Brochet B , Filippi M , Miller DH et al. Diagnostic criteria for primary progressive multiple sclerosis: a position paper . Ann Neurol 2000; 47: 831-835 .

Ramsaransing G , Maurits N , Zwanikken C , De Keyser J. Early prediction of a benign course of multiple sclerosis on clinical grounds: a systematic review . Mult Scler 2001; 7: 345-347 .

10.

Firth SM , Baxter RC. Cellular actions of the insulin-like growth factor binding proteins . Endocr Rev 2002; 23: 824-854 .

11.

Butt AJ , Williams AC.

IGFBP-3 and apoptosis-a license to kill?

Apoptosis 2001; 6: 199-205 .

12.

Baxter RC. Signalling pathways involved in antiproliferative effects of IGFBP-3: a review . Mol Pathol 2001; 54: 145-148 .

13.

Weinzimer SA , Gibson TB , Collett-Solberg PF , Khare A , Liu B , Cohen P. Transferrin is an insulin-like growth factor-binding protein-3 binding protein . J Clin Endocrinol Metab 2001; 86: 1806-1813 .

14.

Li H , Sun H , Qian ZM. The role of the transferrin-transferrin-receptor system in drug delivery and targeting . Trends Pharmacol Sci 2002; 23: 206-209 .

15.

Modric T , Silha JV , Shi Z , Gui Y , Suwanichkul A , Durham SK et al. Phenotypic manifestations of insulin-like growth factor-binding protein-3 overexpression in transgenic mice . Endocrinology 2001; 142: 1958-1967 .

16.

Rensink AA , Gellekink H , Otte-Holler I , ten Donkelaar HJ , de Waal RM , Verbeek MM et al. Expression of the cytokine leukemia inhibitory factor and pro-apoptotic insulin-like growth factor binding protein-3 in Alzheimer’s disease . Acta Neuropathol (Berl) 2002; 104: 525-533 .

17.

Lovett-Racke AE , Bittner P , Cross AH , Carlino JA , Racke MK. Regulation of experimental autoimmune encephalomyelitis with insulin-like growth factor (IGF-1) and IGF-1/IGF-binding protein-3 complex (IGF-1/IGFBP3) . J Clin Invest 1998; 101: 1797-1804 .

18.

Fazekas F , Strasser-Fuchs S , Kollegger H , Berger T , Kristoferitsch W , Schmidt H et al. Apolipoprotein E epsilon 4 is associated with rapid progression of multiple sclerosis . Neurology 2001; 57: 853-857 .

19.

Chapman J , Vinokurov S , Achiron A , Karussis DM , Mitosek-Szewczyk K , Birnbaum M et al. APOE genotype is a major predictor of long-term progression of disability in MS . Neurology 2001; 56: 312-316 .

20.

Savettieri G , Andreoli V , Bonavita S , Cittadella R , Caltagirone C , Fazio MC et al. Apolipoprotein E genotype does not influence the progression of multiple sclerosis . J Neurol 2003; 250: 1094-1098 .